Association Between Right Ventricular Dysfunction and Cardiac Allograft Vasculopathy in Pediatric Patients Following Heart Transplantation

The authors demonstrated that echocardiographic right ventricular (RV) dysfunction, indicated by reduced RV longitudinal strain and strain rate, was an early marker of cardiac allograft vasculopathy (CAV) in pediatric heart transplant recipients [1]. Their findings highlight the potential role of RV functional assessment in noninvasive CAV surveillance. Several issues merit further discussion. Potential confounding factors may have influenced the observed associations. Pediatric heart transplant recipients often receive a variety of heart failure–related medications, including β-blockers, angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and increasingly sodium–glucose cotransporter 2 inhibitors [2]. These drugs may affect RV systolic and diastolic function independently of CAV. It remains unclear whether the prevalence or intensity of heart failure pharmacotherapy differed between patients with and without CAV, which could have introduced bias. Clarification on concomitant medical therapies would strengthen the interpretation. The timing of echocardiographic surveillance requires clarification. Echocardiograms in the CAV group were analyzed both at diagnosis (by coronary angiography) and 6–12 months before, whereas for controls, the study reports that matched echocardiograms were used relative to time from transplantation [1]. However, whether these examinations were truly comparable in terms of clinical stability, immunologic risk, or rejection status is uncertain. Differences in timing or clinical context could have influenced the strain parameters. The absence of significant changes in left ventricular (LV) strain parameters raises important mechanistic questions. The authors speculate that pediatric CAV manifests predominantly as small-vessel disease, potentially sparing the LV [1]. Nonetheless, the specific coronary territories affected (right vs. left coronary artery involvement) may determine whether RV or LV function is impaired. A subgroup analysis examining the relationship between the angiographically involved coronary artery and the ventricular side most affected would provide mechanistic insight. Although early detection of CAV is valuable, optimal management strategies remain unsettled [3]. The study mentions that mTOR inhibitors and statins may slow CAV progression [1], but their routine use in pediatric populations is not yet standardized. Thus, even if RV strain identifies high-risk individuals, the lack of proven pediatric-specific therapies limits immediate clinical impact. Future studies should clarify whether RV functional surveillance can guide personalized immunosuppressive modification or early adjunctive therapies to alter prognosis. The author has nothing to report. The author has nothing to report. The author has nothing to report. The author declares no conflicts of interest. The author has nothing to report.